194 related articles for article (PubMed ID: 33809148)
1. Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; van Marcke C; Caignet X; Mendola A; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809148
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Seront E; Schmitz S; Papier M; van Maanen A; Henry S; Lonchay C; Rottey S; van Caloen G; Machiels JP
Front Oncol; 2019; 9():155. PubMed ID: 30941307
[No Abstract] [Full Text] [Related]
4. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.
Billard-Sandu C; Tao YG; Sablin MP; Dumitrescu G; Billard D; Deutsch E
Eur Arch Otorhinolaryngol; 2020 May; 277(5):1273-1280. PubMed ID: 32162057
[TBL] [Abstract][Full Text] [Related]
6. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
7. p16, HPV, and Cetuximab: What Is the Evidence?
Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Chen D; Sun X; Zhang X; Cao J
Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Fayette J; Wirth L; Oprean C; Udrea A; Jimeno A; Rischin D; Nutting C; Harari PM; Csoszi T; Cernea D; O'Brien P; Hanley WD; Kapp AV; Anderson M; Penuel E; McCall B; Pirzkall A; Vermorken JB
Front Oncol; 2016; 6():232. PubMed ID: 27843803
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
15. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
Young NR; Soneru C; Liu J; Grushko TA; Hardeman A; Olopade OI; Baum A; Solca F; Cohen EE
Target Oncol; 2015 Dec; 10(4):501-8. PubMed ID: 25559287
[TBL] [Abstract][Full Text] [Related]
16. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
17. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
18. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma.
Wong CH; Ma BBY; Hui CWC; Lo KW; Hui EP; Chan ATC
Sci Rep; 2018 May; 8(1):8010. PubMed ID: 29789630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
